​

Dianthus Therapeutics Ownership | Who Owns Dianthus Therapeutics?

OverviewForecastRevenueFinancialsChart

Dianthus Therapeutics Ownership Summary

Dianthus Therapeutics is owned by 43.78% institutional investors, 7.87% insiders, and 48.35% retail investors. Ra capital management is the largest institutional shareholder, holding 8.37% of DNTH shares.

DNTH Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockDianthus Therapeutics43.78%7.87%48.35%
SectorHealthcare Stocks 279.42%10.64%-190.05%
IndustryBiotech Stocks 64.05%10.69%25.27%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ra capital management2.87M8.37%$52.00M
Bain capital life sciences investors2.69M7.86%$48.79M
Deep track capital, lp2.36M6.89%$42.77M
Octagon capital advisors lp2.06M6.02%$38.08M
Vr adviser1.74M5.09%$31.64M
Vestal point capital, lp1.70M4.97%$30.84M
Sio capital management117.00K0.34%$2.12M
Cubist systematic strategies21.82K0.06%$395.78K
Two sigma investments, lp---
Eversource wealth advisors---

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Octagon capital advisors lp2.06M7.37%$38.08M
Bain capital life sciences investors2.69M7.22%$48.79M
Vr adviser1.74M2.69%$31.64M
Vestal point capital, lp1.70M2.20%$30.84M
Deep track capital, lp2.36M1.38%$42.77M
Ra capital management2.87M0.87%$52.00M
Sio capital management117.00K0.63%$2.12M
Cubist systematic strategies21.82K0.00%$395.78K
Two sigma investments, lp---
Eversource wealth advisors---

Top Buyers

HolderShares% AssetsChange
Deep track capital, lp2.36M1.38%2.36M
Ra capital management2.87M0.87%1.00M
Vestal point capital, lp1.70M2.20%625.07K
Sio capital management117.00K0.63%117.00K
Bain capital life sciences investors2.69M7.22%-

Top Sellers

HolderShares% AssetsChange
Janus henderson group---683.62K
Rtw investments, lp---666.67K
Braidwell lp---375.36K
Great point partners---275.00K
Millennium management---90.44K

New Positions

HolderShares% AssetsChangeValue
Deep track capital, lp2.36M1.38%2.36M$42.77M
Sio capital management117.00K0.63%117.00K$2.12M

Sold Out

HolderChange
Creative financial designs inc /adv-10.00
Corecap advisors-11.00
Eversource wealth advisors-13.00
Td private client wealth-17.00
Lindbrook capital-21.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202512-87.23%14,988,897-56.30%430.44%5-90.74%3-86.36%
Dec 31, 2024964.35%35,129,79412.00%1021.22%55-2315.00%
Sep 30, 20249224.32%31,364,8085.60%911.22%5517.02%2025.00%
Jun 30, 202474-2.63%29,702,50213.90%860.84%47-25.40%16100.00%
Mar 31, 202476100.00%26,076,848153.39%1016.32%63231.58%814.29%

Recent Insider Transactions

DateNameRoleActivityValue
Sep 29, 2023Fairmount Funds Management LLC Buy$336.25K
Sep 26, 2023Fairmount Funds Management LLC Buy$394.50K
Sep 19, 2023Fairmount Funds Management LLC Buy$396.00K
Sep 13, 2023Fairmount Funds Management LLC Buy$110.16K
Sep 12, 2023Fairmount Funds Management LLC Buy$161.52K

Insider Transactions Trends

DateBuySell
2025 Q2--
2025 Q1--
2024 Q3--
2024 Q2--
2024 Q1--

DNTH Ownership FAQ

Who Owns Dianthus Therapeutics?

Dianthus Therapeutics shareholders are primarily institutional investors at 43.78%, followed by 7.87% insiders and 48.35% retail investors. The average institutional ownership in Dianthus Therapeutics's industry, Biotech Stocks , is 64.05%, which Dianthus Therapeutics falls below.

Who owns the most shares of Dianthus Therapeutics?

Dianthus Therapeutics’s largest shareholders are Ra capital management (2.87M shares, 8.37%), Bain capital life sciences investors (2.69M shares, 7.86%), and Deep track capital, lp (2.36M shares, 6.89%). Together, they hold 23.12% of Dianthus Therapeutics’s total shares outstanding.

Does Blackrock own Dianthus Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Dianthus Therapeutics.

Who is Dianthus Therapeutics’s biggest shareholder by percentage of total assets invested?

Octagon capital advisors lp is Dianthus Therapeutics’s biggest shareholder by percentage of total assets invested, with 7.37% of its assets in 2.06M Dianthus Therapeutics shares, valued at 38.08M$.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools